Beauty

Novo Nordisk Looks Beyond Weight Loss to Longevity and Aesthetics

Novo’s blockbuster drugs could pull it into buzzier areas of healthcare, chief executive Mike Doustdar said, as the Ozempic maker seeks to lessen its reliance on obesity and diabetes.

Related posts

How ESSEC Business School’s New Master’s Is Evolving Luxury Education

Raven Ward

The Business of Euro Summer

Raven Ward

Asia Feels Full Force of War-Fuelled Energy Crisis

Raven Ward